Home

Overview

Strategy

Intelligence

Publications

Training

Meetings

Slide Presentations

Contact Us

Cardiovascular Biomarkers and Surrogate Endpoints Symposium
Bethesda, Maryland
September 23-24, 2005

As a service to our meeting attendees, the following presentation materials are available for viewing. Please note that material availability is at the discretion of our participating faculty.

If you've installed Windows SP 2, please allow your browser to show active content to view these files.

* - Login Required

1. * Welcome and Conference Objectives - Dr. Jean-Claude Tardif and Dr. Therese Heinonen
2. Pathogenesis of Atherothrombotic Disease and Biomarker Identification - Dr. Peter Libby
3. Is CRP a Validated Biomarker of CV Disease? - Dr. Paul Ridker
4. The Role of Imaging in Disease Detection and Treatment - Dr. Jean-Claude Tardif
5. Markers of Aging and Dementia - Dr. Lewis Kuller
6. * The Need for Biomarkers in Drug Development - Dr. Bill Sasiela
7. The FDA Critical Path Initiative - Opportunities and Challenges - Dr. Douglas Throckmorton
8. How Does the FDA Metabolism and Endocrine Department View Surrogate Endpoints? - Dr. David Orloff
9. * The role of Lipoproteins in Inflammation - Dr. Philip Barter
10. Oxidation in the Pathogenesis of Atherosclerosis - Dr. Jay Heinecke
11. * Special Considerations in Diabetes and Metabolic Syndrome - Dr. Steven Haffner
    
12. * Opportunities for the use of Biomarkers and Surrogate endpoints in the European Union - Dr. Eric Abadie
13. * The Balance Between Safety and Efficacy: Biomarkers as Safety Surrogates - Dr. Eric Brass
14. * Diagnostic and Therapeutic Synergies - Dr. Donald Black
15. Current Status of Disease Assessment with Carotid Ultrasound - Dr. Allen Taylor
16. IVUS As a Surrogate Endpoint - Dr. Steve Nissen
17. Palpography and Elastography as Biomarkers of Cardiovascular Disease - Dr. Ton van der Steen
18. * Advances in Cardiovascular Imaging - Dr. Minh Nguyen
19. * Combined Blood Biomarkers: Diminishing Returns or are More Better - Dr. Wolfgang Koenig
20. Applying Genomics, Proteomics and Metabolomics Technology to Development Programs -
    Dr. Michael Phillips